Publication: Serum pigment epithelium-derived factor levels are increased in patients with biopsy-proven nonalcoholic fatty liver disease and independently associated with liver steatosis
| dc.contributor.author | EREN, FATİH | |
| dc.contributor.author | YILMAZ, YUSUF | |
| dc.contributor.authors | Yilmaz, Yusuf; Eren, Fatih; Ayyildiz, Talat; Colak, Yasar; Kurt, Ramazan; Senates, Ebubekir; Tuncer, Ilyas; Dolar, Enver; Imeryuz, Nese | |
| dc.date.accessioned | 2022-03-12T18:04:56Z | |
| dc.date.accessioned | 2026-01-11T19:25:36Z | |
| dc.date.available | 2022-03-12T18:04:56Z | |
| dc.date.issued | 2011 | |
| dc.description.abstract | Background: Increased serum concentrations of pigment epithelium-derived factor (PEDF) have been linked to the metabolic syndrome in the general population. However, the relationship between serum PEDF and nonalcoholic fatty liver disease (NAFLD), a hepatic manifestation of the metabolic syndrome, remains unknown. Methods: We assayed serum PEDF levels in 156 patients with biopsy-proven NAFLD and 103 nonsteatotic control subjects who were matched for age and sex. The association between levels of PEDF and clinical, biochemical, and histological phenotypes was examined. Results: NAFLD patients had significantly higher serum PEDF levels (1.97 +/- 0.50 mu g/mL) than control subjects (1.51 +/- 0.49 mu g/mL, Student's t test, P<0.001). Multivariable-adjusted stepwise regression analysis showed that PEDF ([beta] = 0.32, t = 3.13, P = 0.002) and triglycerides ([beta] = 0.22, t = 2.23. P = 0.02) were, in the order they entered into the model, the main independent predictors of steatosis scores in our patients with NAFLD. Conclusions: Serum PEDF levels are significantly increased in patients with biopsy-proven NAFLD and are associated with liver steatosis independently of traditional risk factors. (C) 2011 Elsevier B.V. All rights reserved. | |
| dc.identifier.doi | 10.1016/j.cca.2011.08.025 | |
| dc.identifier.issn | 0009-8981 | |
| dc.identifier.pubmed | 21888902 | |
| dc.identifier.uri | https://hdl.handle.net/11424/230529 | |
| dc.identifier.wos | WOS:000296686100047 | |
| dc.language.iso | eng | |
| dc.publisher | ELSEVIER SCIENCE BV | |
| dc.relation.ispartof | CLINICA CHIMICA ACTA | |
| dc.rights | info:eu-repo/semantics/closedAccess | |
| dc.subject | Pigment epithelium-derived factor | |
| dc.subject | Nonalcoholic fatty liver disease | |
| dc.subject | Enzyme-linked immunosorbent assay | |
| dc.subject | Steatosis | |
| dc.subject | ENDOTHELIAL GROWTH-FACTOR | |
| dc.subject | FACTOR PEDF | |
| dc.subject | METABOLIC SYNDROME | |
| dc.subject | INSULIN-RESISTANCE | |
| dc.subject | ANGIOGENESIS | |
| dc.subject | ACTIVATION | |
| dc.subject | CELLS | |
| dc.title | Serum pigment epithelium-derived factor levels are increased in patients with biopsy-proven nonalcoholic fatty liver disease and independently associated with liver steatosis | |
| dc.type | article | |
| dspace.entity.type | Publication | |
| oaire.citation.endPage | 2299 | |
| oaire.citation.issue | 23-24 | |
| oaire.citation.startPage | 2296 | |
| oaire.citation.title | CLINICA CHIMICA ACTA | |
| oaire.citation.volume | 412 |
